All In Biotech

Drug Trial Radar · NCT05757856

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

An Open-label Phase 2 Study Assessing the Safety, Tolerability and Preliminary Diagnostic Performance of a Radioactive Imaging Agent, NDX-3315 and NDX-3324, in Healthy Adult Participants and Patients With Eosinophilic Esophagitis

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Jan 20, 2023

Primary completion

May 22, 2025

Study completion May 22, 2025

Sponsor

Lead sponsor
NexEos Diagnostics, Inc.Industry
Sponsor type
Industry
First posted
Mar 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).

Conditions

  • Eosinophilic Esophagitis

Interventions

  • NDX-3315Drug

    Oral solution

  • NDX-3324Drug

    Oral solution

  • SPECT/CT ImagingDiagnostic test

    Participants undergo SPECT/CT imaging following administration of NDX-3315 or NDX-3324.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of all participants with AEs following administration of NDX-3315 and NDX-3324Time frame: From start of study drug administration up to End of Study (EOS) ( Up to 3 Weeks)
  2. Peak eosinophil counts per high-power field (HPF)Time frame: Up to 10 days after last dose
  3. Absolute quantification of SPECT imagingTime frame: Up to 45 minutes after dose
  4. Determine Concordance of OutcomesTime frame: Up to 10 Days After Last Dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Northwestern Univerisity

    Chicago, Illinois

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.